These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24488323)

  • 1. Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer.
    Mukai H; Takahashi S; Nozawa M; Onozawa Y; Miyazaki J; Ohno K; Suzuki K;
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):703-10. PubMed ID: 24488323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
    Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
    Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
    Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
    Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
    Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
    Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
    Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
    Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.
    Yamamoto N; Boku N; Minami H
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):129-36. PubMed ID: 19437020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
    Sarantopoulos J; Mita AC; He A; Wade JL; Hsueh CT; Morris JC; Lockhart AC; Quinn DI; Hwang J; Mier J; Zhang W; Wack C; Yin J; Clot PF; Rixe O
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):339-351. PubMed ID: 28058445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
    BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m
    Matsuyama H; Matsubara N; Kazama H; Seto T; Tsukube S; Suzuki K
    BMC Cancer; 2020 Jul; 20(1):649. PubMed ID: 32660451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
    van Dodewaard-de Jong JM; Bouman-Wammes EW; Bloemendal HJ; Verheul HMW; de Klerk JMH; van den Eertwegh AJM
    Clin Nucl Med; 2017 Jun; 42(6):415-420. PubMed ID: 28263212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Ito T; Kanao K; Takahara K; Ando R; Yasui T; Shiroki R; Sumitomo M; Miyake H
    Anticancer Res; 2019 Jun; 39(6):3089-3094. PubMed ID: 31177153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Med Oncol; 2017 Aug; 34(8):141. PubMed ID: 28718092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
    Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
    Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
    Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.